Cost-effectiveness: maximizing impact by meticulous data

被引：2

作者：

Blommestein, Hedwig M. ^{[1
]}

Zweegman, Sonja ^{[2
,3
]}

机构：

[1] Erasmus Univ, Rotterdam, Netherlands

[2] Amsterdam UMC, Amsterdam, Netherlands

[3] Canc Ctr Amsterdam, Amsterdam, Netherlands

来源：

BLOOD | 2022年 / 140卷 / 06期

关键词：

DEXAMETHASONE; LENALIDOMIDE;

D O I：

10.1182/blood.2022016958

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this issue of Blood, Yamamoto et al(1) report that treatment with first-line daratumumab in combination with bortezomib, thalidomide, and dexamethasone (Dara-VTd) or lenalidomide, bortezomib, dexamethasone (Dara-RVd) resulted in increased quality adjusted life years (QALYs) and lower costs compared with deferring daratumumab treatment to the second line in combination with carfilzomib and dexamethasone (Dara-Kd).

引用

页码：525 / 526

页数：2

共 8 条

[1] Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma [J].

Attal, Michel ;

Lauwers-Cances, Valerie ;

Hulin, Cyrille ;

Leleu, Xavier ;

Caillot, Denis ;

Escoffre, Martine ;

Arnulf, Bertrand ;

Macro, Margaret ;

Belhadj, Karim ;

Garderet, Laurent ;

Roussel, Murielle ;

Payen, Catherine ;

Mathiot, Claire ;

Fermand, Jean P. ;

Meuleman, Nathalie ;

Rollet, Sandrine ;

Maglio, Michelle E. ;

Zeytoonjian, Andrea A. ;

Weller, Edie A. ;

Munshi, Nikhil ;

Anderson, Kenneth C. ;

Richardson, Paul G. ;

Facon, Thierry ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc ;

Moreau, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) :1311-1320

[2] Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma [J].

Blommestein, Hedwig M. ;

Franken, Margreet G. ;

van Beurden-Tan, Chrissy H. Y. ;

Blijlevens, Nicole M. A. ;

Huijgens, Peter C. ;

Sonneveld, Pieter ;

Uyl-de Groot, Carin A. ;

Zweegman, Sonja .

JAMA NETWORK OPEN, 2021, 4 (03)

[3] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma [J].

Dimopoulos, M. A. ;

Oriol, A. ;

Nahi, H. ;

San-Miguel, J. ;

Bahlis, N. J. ;

Usmani, S. Z. ;

Rabin, N. ;

Orlowski, R. Z. ;

Komarnicki, M. ;

Suzuki, K. ;

Plesner, T. ;

Yoon, S. -S. ;

Ben Yehuda, D. ;

Richardson, P. G. ;

Goldschmidt, H. ;

Reece, D. ;

Lisby, S. ;

Khokhar, N. Z. ;

O'Rourke, L. ;

Chiu, C. ;

Qin, X. ;

Guckert, M. ;

Ahmadi, T. ;

Moreau, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14) :1319-1331

[4] Frequentist and Bayesian meta-regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data [J].

Hatswell, Anthony J. ;

Burns, Darren ;

Baio, Gianluca ;

Wadelin, Frances .

HEALTH ECONOMICS, 2019, 28 (05) :653-665

[5] Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma [J].

Patel, Kishan K. ;

Giri, Smith ;

Parker, Terri L. ;

Bar, Noffar ;

Neparidze, Natalia ;

Huntington, Scott F. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (10) :1119-+

[6] A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma [J].

Seefat, Maarten R. ;

Cucchi, David G. J. ;

Dirven, Stijn ;

Groen, Kaz ;

Zweegman, Sonja ;

Blommestein, Hedwig M. .

CANCERS, 2021, 13 (22)

[7] Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma [J].

Yamamoto, Chihiro ;

Minakata, Daisuke ;

Koyama, Shunsuke ;

Sekiguchi, Kaoru ;

Fukui, Yuta ;

Murahashi, Rui ;

Nakashima, Hirotomo ;

Matsuoka, Sae ;

Ikeda, Takashi ;

Kawaguchi, Shin-ichiro ;

Toda, Yumiko ;

Ito, Shoko ;

Nagayama, Takashi ;

Umino, Kento ;

Nakano, Hirofumi ;

Morita, Kaoru ;

Yamasaki, Ryoko ;

Ashizawa, Masahiro ;

Ueda, Masuzu ;

Hatano, Kaoru ;

Sato, Kazuya ;

Ohmine, Ken ;

Fujiwara, Shin-ichiro ;

Kanda, Yoshinobu .

BLOOD, 2022, 140 (06) :594-607

[8] Modeling Treatment Sequences in Pharmacoeconomic Models [J].

Zheng, Ying ;

Pan, Feng ;

Sorensen, Sonja .

PHARMACOECONOMICS, 2017, 35 (01) :15-24

← 1 →